FDA Approves Lynparza for Maintenance Treatment of BRCA-Mutant Gynecologic Cancers

December 19, 2018 5:00 pm

By Brielle Benyon

The Food and Drug Administration (FDA) approved Lynparza (olaparib) for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a

Read more

What Are My Options for Ovarian Cancer Treatment?

December 15, 2018 9:00 am

By Korin Miller

Navigating ovarian cancer treatment options can be overwhelming, but if you have this illness, it’s a part of the process.

There are five major forms of treatment for ovarian cancer. However, the type of ovarian cancer you … Read more

Many Americans Unaware of Promise of Targeted, ‘Personalized’ Medicine

December 7, 2018 7:00 pm

By Dennis Thompson

Medical science has made tremendous advances in “personalized medicine” — drugs that fight cancer and other diseases by boosting the immune system or targeting specific genetic traits.

Former U.S. President Jimmy Carter benefited from one of these

Read more

From Standard to Personalised Care

November 17, 2018 7:00 pm

Woman with ovarian cancer has incredible response to treatment selected based on her tumor molecular profile. This tumor testing is part of the tumor blueprint that Clearity provides.

By Pierre Valette

“It was definitely a ‘holy smokes’ moment,” recounts Justin … Read more

Taking A Wider View Of Precision Oncology

August 6, 2018 11:06 pm

Proponents of precision medicine cite the growing numbers of successful precision cancer drugs. The examples of Herceptin (trastuzumab), Gleevec (imatinib mesylate), Xalkori (crizotinib), and Zelboraf (vemurafenib) come to mind. Skeptics, on the other hand, focus on the … Read more

FDA Approves Bevacizumab Plus Chemotherapy in Advanced OC

June 14, 2018 7:32 pm

Today, the U.S. Food and Drug Administration (FDA) approved bevacizumab (Avastin) in combination with chemotherapy (carboplatin and paclitaxel) followed by bevacizumab as a single agent for the treatment of women with advanced (stage III or IV) ovarian cancer following initial … Read more

FDA Clears Paxman Scalp-Cooling System

June 12, 2018 6:23 pm

The FDA granted expanded clearance to the Paxman Scalp Cooling System, allowing the device to be used by patients with any type of solid tumor.

The Paxman Scalp Cooling System (Paxman) — designed to reduce hair loss among patients who … Read more

Precision Medicine: A New Era for Ovarian Cancer

September 6, 2017 4:46 pm

By: Laura L. Holman, MD, MS

We’ve come a long way in treating ovarian cancer. This treatment has historically consisted of debulking surgery for nearly every patient, but it is evolving to become more informed and precise. Diagnostic laparoscopy, for … Read more

PARP Inhibitors Changing the Landscape of Ovarian Cancer Treatment

July 11, 2017 5:53 pm

With the FDA approval of two new PARP inhibitor drugs since last year’s Ovarian Cancer National Conference, it’s no surprise the topic was of great interest at this year’s meeting in Chicago, and a standing-room-only crowd was on hand July … Read more